GFM
CTNM

GF Fund Management’s Contineum Therapeutics CTNM Stock Holding History

GF Fund Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.7K Buy
513
+59
+13% +$791 ﹤0.01% 590
2025
Q4 		$5.19K Buy
+454
New +$5.18K ﹤0.01% 623

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GF Fund Management's CTNM Position: Q1 2026 in Review

GF Fund Management increased its Contineum Therapeutics (CTNM) stake by 13% in Q1 2026, buying an estimated $791 and bringing the position to 513 shares worth $6.7K. The position accounts for ﹤0.01% of the portfolio, ranked #590.

GF Fund Management first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • GF Fund Management held 513 shares of Contineum Therapeutics worth $6.7K as of Q1 2026.
  • GF Fund Management bought 59 Contineum Therapeutics shares in Q1 2026, an estimated $791.
  • Contineum Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #590 holding.
  • GF Fund Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.